Association of IL-28 Single Nucleotide Polymorphisms with SVR Rates in HCV Patients within the Asia-Pacific Region

MSD PHARMACEUTICALS PVT LTD0 个研究点目标入组 1,330 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•(1)Patients of Asian ethnicity.
•(2)Patients diagnosed with chronic HCV genotype 1 (only).
•(3)Patients initiated on PegIFN-Î± and ribavirin combination therapy with the last dose completed 6 months prior to and treated within the last 5 years from the date of centre initiation.
•(4)Patients naÃ¯ve to previous PegIFN-Î± and ribavirin combination therapy.
•(5)Patients willing to provide consent and a blood sample for IL-28B analysis.
•(6)Patients aged 18 years and above.

•(1)Co-infected HCV patients (HBV and HIV).
•(2)Active intravenous drug users at the start of combination therapy.
•(3)Known chronic alcoholic at the start of combination therapy (in the judgement of the physician).
•(4)Patients with decompensated liver disease or other causes of liver disease (such as autoimmune hepatitis) at the start of combination therapy.
•(5)Patients suffering from chronic renal failure.
•(6)Patients suffering from thalassemia.
•(7)Patients that have undergone a liver transplantation before or during the PegIFN+ribavirin treatment course.
•(8)Patients with evidence of hepatocellular carcinoma at the start of combination therapy.
•((9)Patients of mixed ethnicity (e.g. White Caucasian and Asian mix, etc.).
•(10)Patients who are currently pregnant.

发起方

MSD PHARMACEUTICALS PVT LTD